ACRS - Inflammatory Disease Focused Aclaris Therapeutics Reduces Staff After Failed Psoriatic Arthritis Study | Benzinga
Aclaris Therapeutics Inc (NASDAQ: ACRS) announced the publication of the Phase 2a trial results of ATI-1777 in moderate to severe atopic dermatitis (AD) in the peer-reviewed journal JID Innovations.
In the Phase 2a study, ATI-1777 demonstrated meaningful improvement in the modified Eczema Area and Severity Index over four weeks of treatment and minimal measurable systemic exposure with a 2% formulation applied twice daily.
Aclaris progressed ATI-1777 into a Phase 2b trial ...